| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Obstetrics and Gynecology (N.A.K., B.S.H., K.R.H., M.R.S.) and Medicine (W.J.B.), University of Washington, Seattle, Washington 98105; Departments of Neurobiology and Physiology (T.K.W.), Northwestern University, Evanston, Illinois 60208; and Reproductive Endocrine Unit Department of Medicine (P.M.S.), Massachusetts General Hospital, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Nancy A. Klein, M.D., Division of Reproductive Endocrinology, 4225 Roosevelt Way NE, Suite 305, Seattle, Washington 98105. E-mail: nklein{at}u.washington.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
During the normal menstrual cycle, FSH begins to rise in the late luteal or early follicular phase, reaches a peak in the early follicular phase, and subsequently falls throughout the remainder of the follicular phase in response to negative feedback from ovarian steroids and/or inhibin (12, 13). The monotropic FSH elevation observed in older women is present throughout the menstrual cycle; however, it is most pronounced in the early follicular phase (3, 4). In older women with regular menses, the early follicular phase FSH peak occurs earlier in the cycle and reaches a greater magnitude (4).
To fully understand the relative roles of inhibin and activin in reproductive aging, it is important to carefully examine changes in their serum profiles during the luteal follicular transition or intercycle period (the interval encompassing the late luteal phase of one cycle and the early follicular phase of the subsequent cycle). Thus, the objectives of the current study were to determine whether reproductive aging in normal ovulatory women is associated with changes in circulating levels of inhibin A, inhibin B, and/or activin A during this critical intercycle period.
| Subjects and Methods |
|---|
|
|
|---|
As part of a series of clinical studies to examine the normal reproductive aging process, we recruited healthy, ovulatory women aged 4045 yr (n = 16) and 2025 yr (n = 13) for participation in this study. All participants were required to have regular menstrual cycles, normal body mass index (1824 kg/m2), absence of medical or reproductive disorders (including any history of infertility), and midluteal serum levels of prolactin less than 20 pg/ml, progesterone more than 10 nmol/liter, and testosterone less than 3 nmol/liter in a prestudy cycle. Women who engaged in greater than 5 h/wk of aerobic exercise were excluded. For the duration of the study, all participants were either sexually abstinent or used nonhormonal methods of contraception. Written consent was obtained, and monetary compensation was provided to all volunteers. The protocol was reviewed and approved by the University of Washington Human Subjects Review Committee.
Protocol and procedures
To completely capture the intercycle FSH peak, daily blood samples were collected during one complete menstrual cycle and continued throughout the subsequent follicular phase in all volunteers. All serum samples were analyzed in duplicate in the same assay to minimize effects of interassay variability. In addition, participants underwent daily transvaginal ultrasound monitoring of dominant follicle development beginning in the midfollicular phase and continuing until follicle collapse was observed. Ultrasound examinations were performed by one of the investigators using an Ultramark 400C (ATL Ultrasound, Bothell, WA) with a 6.5-MHz vaginal transducer. Follicle sizes were estimated by calculating the mean of the two greatest perpendicular diameters in a two-dimensional plane.
Serum FSH levels were determined using a solid-phase two-site monoclonal ELISA (DELFIA, Wallac Inc., Gaithersburg, MD). The intra- and interassay coefficients of variation (CV) were 1.9 and 8.9%, respectively.
Samples were analyzed for LH by an immunoradiometric method (MAIA clone; Serono Laboratories, Geneva, Switzerland). The intra- and interassay CV were 3.9 and 14.6%, respectively.
The RIA for serum estradiol was performed using reagents supplied by ICN Biomedicals, Inc. (Costa Mesa, CA). The intra- and interassay CV were 9 and 18%, respectively.
Serum P was determined by solid-phase RIA using reagents supplied by Diagnostic Systems Laboratories, Inc. (Webster, TX). The antibody cross-reactivity is less than 5% with all other steroids. The intra- and interassay CV were 11 and 13%, respectively.
A solid-phase sandwich ELISA (Serotec, Oxford, UK) was used to measure inhibin B, based on the use of plates coated with a monoclonal antibody specific for the inhibin ß-B subunit with a second monoclonal antibody specific for the inhibin
-subunit for detection. The sensitivity was 15.6 pg/ml, and inhibin A had a 0.5% cross-reaction in the inhibin B ELISA. The assay was controlled in triplicate using samples with mean concentrations of 155.3, 316.3, and 919.3 pg/ml, with interassay CV of 11.6, 7.6, and 9.7%, respectively.
Inhibin A was analyzed by a solid-phase sandwich ELISA (Diagnostic Systems Laboratories). This assay uses a monoclonal first antibody specific for the ß-A subunit of inhibin, with a horseradish peroxidase-labeled monoclonal second antibody specific for the
-subunit for detection. The assay standard provided by the manufacturer was calibrated using the World Health Organizations First International Standard for Inhibin (recombinant human inhibin; lot 91/624), and results are reported as international units per milliliter of this reference material. Sensitivity of the assay was 0.1 IU/ml. The assay was controlled in duplicate using aliquots of specimens containing 2.00 or 9.56 IU/ml, with interassay CV of 8.7 and 3.3%, respectively.
Activin A was measured by a solid-phase sandwich ELISA (Diagnostic Systems Laboratories) using monoclonal antibody specific for the ß-A subunit followed by a biotinylated monoclonal antibody and streptavidin-alkaline phosphatase for detection. Samples were pretreated with sodium dodecyl sulfate to avoid interference of bound follistatin. The detection limit is 10 pg/ml, and recovery is 102 + 3% for bovine follicular fluid and 96 + 5% for human serum. Cross-reactivity is less than 0.5% for inhibin A, B, and activin B and less than 0.1% for pro-
-C and follistatin. The assay was performed in duplicate with control samples of 0.15, 1.25, and 7.5 pg/ml with intra/interassay CV of 4.5 and 14, 3.4 and 12, and 7.5 and 11%, respectively.
Statistical analysis
Results are expressed as means ± SE. Two-way ANOVA with repeated measures was used to test for differences between groups over the menstrual cycle. Single -oint measurements were compared using a Students t test. Statistical significance was defined as P < 0.05 in all cases.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
Using assays specific for dimeric inhibin, several investigators have reported that inhibin B is low in the follicular phase of older women exhibiting a monotropic FSH elevation (6, 7, 8, 9, 10, 11). Inhibin B levels inversely correlate with FSH and positively correlate with the number of small (<5 mm) antral follicles present by transvaginal ultrasound (19). It is likely that this decrease in inhibin B concentration is the result of fewer primordial and early antral follicles remaining in the ovaries of older women (20, 21). Previous studies of inhibin A secretion in reproductive aging have produced conflicting results, with some investigators reporting low inhibin A secretion (5, 6, 8, 10) and others reporting normal levels in older, ovulatory women (7, 9, 11). In the present study, there was no evidence that inhibin A is deficient in early stages of reproductive aging after the onset of the monotropic FSH rise. The fact that overall inhibin A secretion appears to be higher in the older women suggests that it is inhibin B and not inhibin A that is responsible for the monotropic FSH rise. This is consistent with previous evidence that inhibin A is not a major determinant of the early follicular phase FSH rise in normal reproductive-age women (9, 22). Others have reported that inhibin A was normal in older women without FSH elevation but was decreased in older participants who demonstrated a monotropic FSH rise (8). Welt et al. (11) found no differences in luteal phase levels of inhibin A between older (age, 3546 yr) and younger (age, <35) ovulatory women; however, inhibin A levels declined with age in all three women studied longitudinally. Thus, it appears that inhibin B but not A declines in the earliest stages of reproductive aging, in contrast to the decrease in inhibin A levels that has been previously reported (5, 6, 8, 10, 11). Taken together, available data on inhibin A suggest that a decrease in this hormone may represent a later development during reproductive aging.
In contrast to previous reports by other investigators (9, 10), the current study did not detect a significant increase in circulating activin A levels. Possible explanations include relatively small sample sizes and differences in the characteristics of the study populations. Activin A has been shown to increase with age in both men and women and does not correlate with FSH levels in either gender (23, 24). Furthermore, mRNA for activin subunits is expressed in a number of extragonadal tissues (25), is present predominantly in a bound (and therefore inactive) form in the circulation (26), and does not vary across the menstrual cycle despite marked variability in FSH levels. Although our current understanding of activin physiology is limited by the lack of available assays for other activin forms (e.g. activin B, activin AB), to date there is little evidence to support an endocrine role for activin in FSH regulation.
Similar to the elevated estradiol (11, 27, 28) and normal progesterone levels (3, 4) observed in older women demonstrating a monotropic FSH rise, normal or increased inhibin A may be a result of FSH elevation. In previous studies of 40- to 45-yr-old ovulatory women, we found normal follicular fluid concentrations of steroids and inhibin (28, 29, 30). Together with normal peripheral levels of progesterone and normal to increased levels of estradiol and inhibin A, these findings suggest that, under the influence of FSH elevation, the dominant follicle is fully functional in terms of its secretory capacity. Thus, FSH elevation may represent a compensatory mechanism in response to declining inhibin B secretion from a diminishing follicle pool, sufficient in early stages to maintain normal dominant follicle development and ovulation. By recruiting only women who reported very regular menstrual cycles, we selected women who were in a relatively early stage of reproductive aging (i.e. equivalent to stage 4 or 3 according to the Stages of Reproductive Aging Workshop) (30). Cross-sectional and longitudinal studies reported by others (5, 11) suggest that inhibin A levels eventually decline as women approach the menopausal transition, which represents a more advanced stage of reproductive aging.
Previous studies of inhibin secretion have been limited by sampling during only one menstrual cycle. Due to the dynamic interactions of hormones across the menstrual cycle, comparisons between groups require normalizing data to a specific point in the cycle (traditionally, the midcycle LH surge). Relative to the menstrual period, older reproductive-age women have an earlier onset of the monotropic FSH rise (4) and shorter follicular phase length (1, 4, 23, 31) such that normalization to the LH surge does not allow for comparison of hormones in the early follicular phase. The onset of menses is an end-organ response to falling ovarian steroids and, as such, is a crude and inaccurate indicator of the beginning of the follicular phase (13). Therefore, to study the relationship between inhibin and FSH, it was important to examine the entire intercycle phase so that the intercycle FSH peak could be identified and the associated hormonal patterns compared relative to this important physiological time point.
In summary, this study more precisely characterizes the role of the inhibin and activin glycoprotein hormones in early reproductive aging. The finding of an isolated inhibin B deficiency in the face of normal estradiol, activin A, and inhibin A supports the notion that inhibin B may be the primary mediator of the monotropic rise in FSH. Thus, a decline in inhibin B may be a sensitive marker of the earliest stages of ovarian senescence.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviation: CV, Coefficient(s) of variation.
Received August 29, 2003.
Accepted February 23, 2004.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C.H. de Koning, J. McDonnell, A.P.N. Themmen, F.H. de Jong, R. Homburg, and C.B. Lambalk The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls Hum. Reprod., June 1, 2008; 23(6): 1416 - 1423. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.G. Burger, G.E. Hale, D.M. Robertson, and L. Dennerstein A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project Hum. Reprod. Update, November 1, 2007; 13(6): 559 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S Malhi, G. P Adams, R. J Mapletoft, and J. Singh Oocyte developmental competence in a bovine model of reproductive aging Reproduction, August 1, 2007; 134(2): 233 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Hale, X. Zhao, C. L. Hughes, H. G. Burger, D. M. Robertson, and I. S. Fraser Endocrine Features of Menstrual Cycles in Middle and Late Reproductive Age and the Menopausal Transition Classified According to the Staging of Reproductive Aging Workshop (STRAW) Staging System J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3060 - 3067. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Perrien, N. S. Akel, P. K. Edwards, A. A. Carver, M. S. Bendre, F. L. Swain, R. A. Skinner, W. R. Hogue, K. M. Nicks, T. M. Pierson, et al. Inhibin A Is an Endocrine Stimulator of Bone Mass and Strength Endocrinology, April 1, 2007; 148(4): 1654 - 1665. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.A. O'Connor, E. Brindle, R.C. Miller, J.B. Shofer, R.J. Ferrell, N.A. Klein, M.R. Soules, D.J. Holman, P.K. Mansfield, and J.W. Wood Ovulation detection methods for urinary hormones: precision, daily and intermittent sampling and a combined hierarchical method Hum. Reprod., June 1, 2006; 21(6): 1442 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Lambert-Messerlian and B. L. Harlow The Influence of Depression, Body Mass Index, and Smoking on Serum Inhibin B Levels in Late Reproductive-Aged Women J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1496 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.H. de Koning, T. Benjamins, P. Harms, R. Homburg, J.M. van Montfrans, J. Gromoll, M. Simoni, and C.B. Lambalk The distribution of FSH receptor isoforms is related to basal FSH levels in subfertile women with normal menstrual cycles Hum. Reprod., February 1, 2006; 21(2): 443 - 446. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Wu, M. B. Zelinski, D. K. Ingram, and M. A. Ottinger Ovarian Aging and Menopause: Current Theories, Hypotheses, and Research Models Experimental Biology and Medicine, December 1, 2005; 230(11): 818 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Malhi, G. P. Adams, and J. Singh Bovine Model for the Study of Reproductive Aging in Women: Follicular, Luteal, and Endocrine Characteristics Biol Reprod, July 1, 2005; 73(1): 45 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Hansen, A. C. Thyer, P. M. Sluss, W. J. Bremner, M. R. Soules, and N. A. Klein Reproductive ageing and ovarian function: is the early follicular phase FSH rise necessary to maintain adequate secretory function in older ovulatory women? Hum. Reprod., January 1, 2005; 20(1): 89 - 95. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |